Surgery Partners, Inc.
SGRY
$24.05
-$0.11-0.46%
Weiss Ratings | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.43 | |||
Price History | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -3.99% | |||
30-Day Total Return | 16.69% | |||
60-Day Total Return | 9.87% | |||
90-Day Total Return | -22.09% | |||
Year to Date Total Return | 12.96% | |||
1-Year Total Return | -19.86% | |||
2-Year Total Return | -25.33% | |||
3-Year Total Return | -53.43% | |||
5-Year Total Return | 146.16% | |||
52-Week High % Change | -28.88% | |||
52-Week Low % Change | 23.90% | |||
Price | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $33.97 | |||
52-Week Low Price | $19.50 | |||
52-Week Low Price (Date) | Dec 20, 2024 | |||
52-Week High Price (Date) | Aug 26, 2024 | |||
Valuation | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 3.05B | |||
Enterprise Value | 8.00B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.48 | |||
Earnings Per Share Growth | 49.95% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 1.02 | |||
Price/Book (Q) | 1.61 | |||
Enterprise Value/Revenue (TTM) | 2.68 | |||
Price | $24.05 | |||
Enterprise Value/EBITDA (TTM) | 13.40 | |||
Enterprise Value/EBIT | 17.89 | |||
Market Cap Category | Mid Cap | |||
Dividends and Shares | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 126.17M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 615 234 5900 | |||
Address | 340 Seven Springs Way Brentwood, TN 37027 | |||
Website | www.surgerypartners.com | |||
Country | United States | |||
Year Founded | 2004 | |||
Profitability | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 14.98% | |||
Profit Margin | -2.02% | |||
Management Effectiveness | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 3.91% | |||
Return on Equity | 3.08% | |||
Income Statement | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 2.99B | |||
Total Revenue (TTM) | 2.99B | |||
Revenue Per Share | $23.66 | |||
Gross Profit (TTM) | 705.60M | |||
EBITDA (TTM) | 597.00M | |||
EBIT (TTM) | 447.20M | |||
Net Income (TTM) | -60.60M | |||
Net Income Avl. to Common (TTM) | -60.60M | |||
Total Revenue Growth (Q YOY) | 14.29% | |||
Earnings Growth (Q YOY) | -78.45% | |||
EPS Diluted (TTM) | -0.48 | |||
EPS Diluted Growth (Q YOY) | -528.00% | |||
Balance Sheet | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 243.50M | |||
Cash Per Share (Q) | $1.93 | |||
Total Current Assets (Q) | 1.04B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 3.55B | |||
Current Ratio (Q) | 1.801 | |||
Book Value Per Share (Q) | $15.00 | |||
Total Assets (Q) | 7.53B | |||
Total Current Liabilities (Q) | 575.20M | |||
Total Debt (Q) | 3.53B | |||
Total Liabilities (Q) | 3.99B | |||
Total Common Equity (Q) | 1.90B | |||
Cash Flow | SGRY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -434.90M | |||
Cash from Financing (TTM) | 169.40M | |||
Net Change in Cash (TTM) | -14.20M | |||
Levered Free Cash Flow (TTM) | 141.86M | |||
Cash from Operations (TTM) | 251.30M | |||